RxDoctor Payments Data

Ashleigh Gehret

Family · Reading, PANPI 1265993307

Payments from drug & device makers

$8,743in general payments, 2019–2025

Across 474 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$627
  • Amgen$562
  • AstraZeneca$472
  • Lilly USA, LLC$449
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$8,713100%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,743 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,036
Medicare patients
345
Services billed
1,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$125,639
OzempicSemaglutide86$93,282
JardianceEmpagliflozin48$62,050
XareltoRivaroxaban31$31,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$29,668
Tresiba Flextouch U-200Insulin Degludec20$28,818
MyrbetriqMirabegron48$28,199
WegovySemaglutide18$27,386
Soliqua 100-33Insulin Glargine/Lixisenatide20$26,695
FarxigaDapagliflozin Propanediol27$26,693
JanuviaSitagliptin Phosphate22$26,244
LinzessLinaclotide20$13,081
MounjaroTirzepatide12$12,281
ArexvyRsvpref3 Antigen/As01e/Pf20$6,213
ShingrixVaricella-Zoster Ge/As01b/Pf22$4,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$627$125,639146 claims
Novo NordiskOzempic, Wegovy$1,314$120,668104 claims
Boehringer IngelheimJardiance$236$62,05048 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$226$40,77782 claims
Johnson & JohnsonXarelto$17$31,67731 claims
MerckJanuvia, Janumet Xr$169$30,58334 claims
Astellas Pharma US IncMyrbetriq$167$28,19948 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$175$26,69520 claims
AstraZenecaFarxiga$472$26,69327 claims
AbbVieLinzess, Synthroid$1,865$17,23677 claims
Lilly USA, LLCMounjaro$449$12,28112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$4,057435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →